CL2015001708A1 - Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón. - Google Patents
Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón.Info
- Publication number
- CL2015001708A1 CL2015001708A1 CL2015001708A CL2015001708A CL2015001708A1 CL 2015001708 A1 CL2015001708 A1 CL 2015001708A1 CL 2015001708 A CL2015001708 A CL 2015001708A CL 2015001708 A CL2015001708 A CL 2015001708A CL 2015001708 A1 CL2015001708 A1 CL 2015001708A1
- Authority
- CL
- Chile
- Prior art keywords
- igf
- mutated
- polynucleotide
- insulin
- polypeptide
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title 1
- 239000004471 Glycine Substances 0.000 title 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title 1
- 101150088952 IGF1 gene Proteins 0.000 title 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 title 1
- 208000021642 Muscular disease Diseases 0.000 title 1
- 208000011623 Obstructive Lung disease Diseases 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738475P | 2012-12-18 | 2012-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001708A1 true CL2015001708A1 (es) | 2015-08-28 |
Family
ID=50073229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001708A CL2015001708A1 (es) | 2012-12-18 | 2015-06-17 | Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón. |
Country Status (36)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052123A1 (en) * | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| KR20180137487A (ko) * | 2016-03-04 | 2018-12-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3813861A4 (en) * | 2018-06-27 | 2022-08-10 | Juvena Therapeutics, Inc. | HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES |
| CN109053875B (zh) * | 2018-08-31 | 2021-06-29 | 重庆大学 | 突变型igf-1、重组质粒、重组蛋白及应用 |
| RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
| CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| CN117999278A (zh) | 2021-06-21 | 2024-05-07 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| EP4652282A2 (en) * | 2023-11-14 | 2025-11-26 | Cavalry Biosciences, Inc. | Compositions for targeting muscle cells and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| WO2000040612A1 (en) * | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| WO2000040613A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| US7083970B2 (en) | 2001-04-19 | 2006-08-01 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| CA2594023C (en) * | 2005-01-07 | 2015-07-14 | Regeneron Pharmaceuticals, Inc. | Igf-i fusion polypeptides and therapeutic uses thereof |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| CN101466398A (zh) * | 2006-06-09 | 2009-06-24 | 诺瓦提斯公司 | 稳定的胰岛素样生长因子多肽 |
| MX2008015726A (es) | 2006-06-09 | 2008-12-19 | Novartis Ag | Polipeptidos de factor de crecimiento de tipo insulina estabilizada. |
| ES2784926T3 (es) | 2007-12-21 | 2020-10-02 | Novartis Ag | Vector de expresión de mamífero |
| HUE035240T2 (hu) | 2009-04-27 | 2018-05-02 | Novartis Ag | Készítmények és eljárások az izomerõ növelésére |
| WO2011011073A1 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| US10030063B2 (en) | 2012-12-18 | 2018-07-24 | Novartis Ag | Production of therapeutic proteins in genetically modified mammalian cells |
| EP3052123A1 (en) | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
-
2013
- 2013-12-16 MA MA38153A patent/MA38153B1/fr unknown
- 2013-12-16 BR BR112015013708-3A patent/BR112015013708B1/pt not_active IP Right Cessation
- 2013-12-16 CN CN201380066090.8A patent/CN105121462B/zh active Active
- 2013-12-16 NZ NZ708091A patent/NZ708091A/en not_active IP Right Cessation
- 2013-12-16 CA CA2894976A patent/CA2894976C/en active Active
- 2013-12-16 WO PCT/IB2013/060985 patent/WO2014097116A1/en not_active Ceased
- 2013-12-16 HR HRP20191965TT patent/HRP20191965T1/hr unknown
- 2013-12-16 MX MX2015007932A patent/MX363021B/es unknown
- 2013-12-16 CU CUP2015000064A patent/CU24308B1/xx unknown
- 2013-12-16 SI SI201331611T patent/SI2935320T1/sl unknown
- 2013-12-16 PL PL13828987T patent/PL2935320T3/pl unknown
- 2013-12-16 EA EA201591165A patent/EA034356B1/ru not_active IP Right Cessation
- 2013-12-16 MY MYPI2015001207A patent/MY174820A/en unknown
- 2013-12-16 JP JP2015547255A patent/JP6499080B2/ja active Active
- 2013-12-16 AP AP2015008440A patent/AP2015008440A0/xx unknown
- 2013-12-16 HU HUE13828987A patent/HUE047386T2/hu unknown
- 2013-12-16 KR KR1020157018991A patent/KR102182523B1/ko active Active
- 2013-12-16 US US14/651,686 patent/US10167329B2/en active Active
- 2013-12-16 PE PE2019002049A patent/PE20200894A1/es unknown
- 2013-12-16 PE PE2015001039A patent/PE20151612A1/es not_active Application Discontinuation
- 2013-12-16 EP EP19191570.1A patent/EP3626735A1/en not_active Withdrawn
- 2013-12-16 CR CR20200079A patent/CR20200079A/es unknown
- 2013-12-16 SG SG11201503782PA patent/SG11201503782PA/en unknown
- 2013-12-16 ES ES13828987T patent/ES2756330T3/es active Active
- 2013-12-16 DK DK13828987T patent/DK2935320T3/da active
- 2013-12-16 AU AU2013365796A patent/AU2013365796B2/en not_active Ceased
- 2013-12-16 EP EP13828987.1A patent/EP2935320B1/en active Active
- 2013-12-16 RS RS20191416A patent/RS59545B1/sr unknown
- 2013-12-16 LT LT13828987T patent/LT2935320T/lt unknown
- 2013-12-16 PT PT138289871T patent/PT2935320T/pt unknown
-
2015
- 2015-05-08 TN TNP2015000182A patent/TN2015000182A1/fr unknown
- 2015-06-04 PH PH12015501271A patent/PH12015501271A1/en unknown
- 2015-06-11 IL IL239387A patent/IL239387A0/en active IP Right Grant
- 2015-06-17 CL CL2015001708A patent/CL2015001708A1/es unknown
- 2015-06-17 SA SA515360603A patent/SA515360603B1/ar unknown
- 2015-06-18 CR CR20150324A patent/CR20150324A/es unknown
- 2015-06-18 GT GT201500168A patent/GT201500168A/es unknown
- 2015-07-17 EC ECIEPI201531046A patent/ECSP15031046A/es unknown
-
2019
- 2019-11-19 CY CY20191101212T patent/CY1122309T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001708A1 (es) | Polipétido que comprende el factor de crecimiento tipo insulina 1 (igf-1), donde el aminoácido glicina en posición 42 es suprimido o mutado; polinucléotido; composición farmacéutica que lo comprende; y uso para tratar un trastorno muscular, enefermedad pulmonar obstructiva o enfermedad crónica de riñón. | |
| CL2012001186A1 (es) | Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal. | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BR112014023374A2 (pt) | composições de peptídeos de glp-1 e preparação das mesmas | |
| CL2014000114A1 (es) | Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor. | |
| CL2013001655A1 (es) | Compuestos bifenilicos sustituidos; composicion farmaceutica; y uso en el tratamiento o prevencion de fibrosis pulmonar, renal, hepatica o cutanea. | |
| CL2014000758A1 (es) | Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral. | |
| CL2014001054A1 (es) | Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra. | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| CL2007000752A1 (es) | Compuestos derivados de heterociclos, inhibidores de la proteina quinasa c-met; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno proliferativo, tales como aterosclerosis o fibrosis pulmonar. | |
| BR112014032938A2 (pt) | uso de peptídeos de glp-1 de longa ação | |
| CL2016001405A1 (es) | A peptide mixture | |
| JP2013523703A5 (cg-RX-API-DMAC7.html) | ||
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| EP4417256A3 (en) | Materials and methods for improving lung function | |
| CL2014003167A1 (es) | Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. | |
| CL2013000475A1 (es) | Polipeptidos de relaxina que comprende uno o mas aminoacidos codificados no naturales; acido nucleico aislado; metodo para preparar el polipeptido de relaxina. | |
| JP2014513951A5 (cg-RX-API-DMAC7.html) | ||
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| CL2014003464A1 (es) | Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa). | |
| CL2014002822A1 (es) | Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v. | |
| IL206450A (en) | Use of a preparation that includes salt of o-acetylsalicylic acid and basic amino acid in the preparation of a drug for the prevention or treatment of viral infections | |
| CL2013003230A1 (es) | Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos. | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé |